Literature DB >> 3119213

Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.

H Nakajima1, Y Izumi, S Sugihara, Y Satoh, S Isumi, T Gotoh, H Fujiwara, T Hamaoka.   

Abstract

In the present study we investigated some of the physicochemical properties of macrophage-activating factor(s) (MAF) produced by the tumor-immune Lyt-1+2- T cell subset. Supernatant from mixed culture of spleen and lymph node cells, obtained from C3H/HeN mice immunized with syngeneic MH134 hepatoma or MCH-1-A1 fibrosarcoma, with the corresponding tumor cells exhibited the capability of activating peritoneal exudate macrophages to exert their cytostatic and cytolytic activities on tumor cells. Such MAF production was abolished by treatment of tumor-immune spleen and lymph node cells with anti-Thy-1.2 or anti-Lyt-1.1 antibody plus complement (C) before culturing. Anti-Lyt-2.1 and/or anti-asialo GM1 plus C treatment, however, had only marginal effect on the generation of MAF by these cells, despite the complete disappearance of natural killer (NK) cell activity of spleen and lymph node cells after the treatment with anti-asialo GM1 plus C. Thus, the tumor-specific Lyt-1+2- T cell subset could fulfill a crucial role in generating MAF without the support of NK cells. The MAF activity was heat, acid, and trypsin sensitive. On Sephacryl S-300 column, MAF activity was eluated in a broad single peak around a molecular weight (m.w.) of 70,000 daltons. Antiviral activity was detected in the concentrated pool of MAF-containing fractions from Sephacryl S-300. Gel permeation analysis using HPLC also showed a coincident peak of MAF and antiviral activities at a m.w. of approximately 70,000 daltons. In addition, MAF activity was almost completely neutralized by incubation with rabbit antiserum against recombinant murine gamma-interferon (IFN gamma). Taken together, these results indicate that MAF generated by tumor-immune Lyt-1+2- T cell subset is closely related to IFN gamma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119213     DOI: 10.1007/bf00199148

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  48 in total

1.  Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.

Authors:  K Sakamoto; H Fujiwara; H Nakajima; T Yoshioka; Y Takai; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1986-11

2.  The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.

Authors:  H Fujiwara; Y Takai; K Sakamoto; T Hamaoka
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

3.  Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity.

Authors:  K Kuribayashi; S Gillis; D E Kern; C S Henney
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

4.  Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.

Authors:  H Nakajima; H Fujiwara; Y Takai; Y Izumi; S Sano; T Tsuchida; T Hamaoka
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

5.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.

Authors:  K Handa; R Suzuki; H Matsui; Y Shimizu; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

6.  T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo.

Authors:  J C Leclerc; H Cantor
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

7.  Similarities of murine gamma interferon and the lymphokine that renders macrophages cytotoxic.

Authors:  W J Kleinschmidt; R M Schultz
Journal:  J Interferon Res       Date:  1982

8.  Positively selected Lyt-2+ and Lyt-2- mouse T lymphocytes are comparable, after Con A stimulation, in release of IL 2 and of lymphokines acting on B cells, macrophages, and mast cells, but differ in interferon production.

Authors:  P A Guerne; P F Piguet; P Vassalli
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

9.  T-cell hybridoma production of macrophage activation factor (MAF) I. Separation of MAF from interferon gamma.

Authors:  T L Ratliff; D L Thomasson; R E McCool; W J Catalona
Journal:  J Reticuloendothel Soc       Date:  1982-05

10.  Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.

Authors:  J L Pace; S W Russell; B A Torres; H M Johnson; P W Gray
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

View more
  2 in total

1.  The mode of recognition of tumor antigens by noncytolytic-type antitumor T cells: role of antigen-presenting cells and their surface class I and class II H-2 molecules.

Authors:  K Sakamoto; H Nakajima; J Shimizu; T Katagiri; C Kiyotaki; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 2.  Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy.

Authors:  G Forni; H Fujiwara; F Martino; T Hamaoka; C Jemma; P Caretto; M Giovarelli
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.